Starting a Beta-Blocker Before Surgery He Doesn't Otherwise Need
A single patient whose pre-operative checklist raised a question that, once worked through, had a clear answer after all.
E.D., a 68-year-old man, worked as a machinist for over four decades, retiring only when the shop where he'd spent his career closed for good. He's scheduled for an elective total hip replacement in three weeks, the culmination of two years of worsening hip pain that finally outlasted his patience for physical therapy and pain management alone.
His cardiac history is real but stable: a myocardial infarction and percutaneous coronary intervention to his left anterior descending artery five years ago, no anginal symptoms since, a normal ejection fraction on his most recent echocardiogram, and a beta-blocker that his cardiologist discontinued three years ago, judging it no longer necessary given his sustained, asymptomatic stability. He remains on aspirin and a statin. The pre-operative anesthesia checklist, built around an older cardiac-risk-reduction protocol, flagged “consider beta-blocker” for his case, which is what brought the question to this visit rather than any change in his actual cardiac status.
The trial that reshaped this question tested extended-release metoprolol started shortly before surgery in beta-blocker-naive patients, and found a genuine tradeoff rather than a clean benefit: fewer non-fatal heart attacks, but more than double the rate of stroke and a meaningfully higher rate of death, driven substantially by drug-induced hypotension and bradycardia during a physiologically vulnerable window. That finding reshaped perioperative cardiac risk protocols broadly, but its most direct lesson is narrower than it's sometimes applied: it says something specific about starting a beta-blocker acutely without an independent indication, not that beta-blockers are generally unsafe perioperatively for patients who already have a real reason to be on one.
Working through a checklist prompt that may not apply
The checklist prompt is why I'm raising this, and I want to be upfront that I'm not certain it still applies to him. The historical rationale was that perioperative beta-blockade reduces cardiac risk in non-cardiac surgery, but I know that evidence has been substantially revised since the protocol this checklist is built on, and I'd rather work through whether it actually fits his case than follow the prompt reflexively.
It doesn't fit him, and I'd say that plainly. The large trial that reshaped this evidence found that starting a beta-blocker specifically for perioperative risk reduction, in patients without their own separate indication for one, increased stroke and death even as it modestly reduced non-fatal heart attacks. He has no current indication for chronic beta-blockade — he's asymptomatic, revascularized, with a normal ejection fraction, and he came off a beta-blocker three years ago without any issue. Starting one now would be treating his surgery, not treating him.
I'd add one clarification for the record, separate from whether he needs one at all: if a beta-blocker were ever going to be started for a genuine indication, the lesson from that trial is that it should happen well in advance of surgery with careful titration, never initiated close to the procedure itself. But that's a different question from this one. The answer here is that he doesn't have an indication, timing aside, and the checklist prompt shouldn't be read as one.
No new beta-blocker started. His existing aspirin and statin continue unchanged, and he proceeds toward his hip replacement in three weeks without any new cardiac medication.
No further cardiac workup or medication change is anticipated beyond routine perioperative monitoring.
The beta-blocker question would be revisited on its own merits, as a genuine new indication rather than a checklist prompt.
The anesthesiologist's willingness to question the checklist rather than follow it was the actual turning point in the conversation — the checklist itself has now been flagged for the surgical team to review, since this is unlikely to be the last patient it prompts a recommendation for that current evidence doesn't support.